Compare Trip.com Group Ltd (TCOM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs Tango Therapeutics Inc. — how do they compare? Trip.com Group Ltd trades at $39.23 (market cap $24.60B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Trip.com Group Ltd is far larger — about 6.6× Tango Therapeutics Inc.'s market cap, and Trip.com Group Ltd pays a 0.42% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trip.com Group Ltd for 80 Days and Tango Therapeutics Inc. for 0 Days on average.
| TCOM | TNGX | |
|---|---|---|
Market Cap | $24.60B | $3.75B |
Volume | 1,981,955 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $32.90 |
52-Week Low | $37.96 | $7.50 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $16.75B | $2.77B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCOM trades at $38.88, up 0.31% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 7.48, net income margin of 36.9%, and robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Recent Q2 2026 earnings beat expectations at $1.07 per share, though Q1 and Q4 2025 missed. Cash flow remains positive with $7.11B net cash flow in 2024, and the balance sheet is healthy with total assets of $242.58B and debt-to-asset ratio improving to 16.37%.
The outlook is mixed: analyst consensus is bullish with a $56.64 price target and 70.45% buy ratings, but regulatory risks and recent antitrust fines pose challenges. Earnings growth and international expansion are key catalysts, yet competition and market volatility require caution. The stock presents value given low valuations, but investors must weigh regulatory headwinds against fundamental strength.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
